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Abstract
Summary Administration of intermittent parathyroid hor-
mone (PTH) promoted healing of tibial osseous defects and
tooth extraction wounds and prevented the development of
necrotic lesions in rats on a combined bisphosphonate and
steroid regimen.
Introduction Osteonecrosis of the jaw (ONJ) has emerged in
association with antiresorptive therapies. The pathophysiolo-
gy of ONJ is unknown and no established cure currently
exists. Our objective was to determine the effect of intermit-
tent PTH administration on early osseous healing in the jaw
and long bones of rats receiving bisphosphonate and steroid
treatment.
Methods Ovariectomized rats received the combination ther-
apy of alendronate and dexamethasone (ALN/DEX) for
12 weeks. Osseous wounds were created in the jaw and tibia.
PTH was administered intermittently and healing at 2 weeks
post-op was compared between the jaw and tibia by
microcomputed tomography and histomorphometric
analyses.
Results ALN/DEX treatment was associated with necrotic
open wounds in the jaw but had no negative effects on healing
and promoted bone fill in tibial defects. PTH therapy
prevented the development of necrotic lesions in the jaw and
promoted healing of the tibial defects. PTH therapy was
associated with the promotion of osteocyte survival in osseous
wounds both in the jaw and tibia.
Conclusions Wound healing was impaired in the jaw in rats
on a combined bisphosphonate and steroid regimen, and PTH
therapy rescued necrotic lesions. These findings suggest that
PTH therapy could be utilized to prevent ONJ from occurring
in patients on combination antiresorptive and steroid therapy.
Keywords Alendronate . Bisphosphonate-associated
osteonecrosis of the Jaw . Parathyroid hormone .
Wound healing
Introduction
Bone fracture and osteotomy cause osteocyte death which
attracts osteoclasts for repair [1]. Osteoclasts are specialized
cells responsible for bone resorption. During osseous wound
healing, osteoclasts play an essential role in removing dam-
aged bone and reshaping newly formed bone. Osteoclasts
emerge in the early phase of osseous wound healing in long
bones not only to resorb damaged bone but to also contribute
to the orchestration of the entire repair process [2, 3]. In the
jaw soon after a tooth extraction, osteoclasts appear on the
crestal bone area to resorb damaged bone [4, 5].
Nitrogen-containing bisphosphonates (N-BP), such as zo-
ledronic acid and alendronate (ALN), are potent
antiresorptives widely used for the management of bone met-
astatic diseases and osteoporosis. Recent reports have shown
that antiresorptive therapy is associated with the development
of osteonecrosis of the jaw (ONJ) [6]. ONJ is a rare and site-
specific complication related to potent antiresorptive therapy
that uniquely occurs in the jaw [7]. The exact mechanism of
this site specificity is not yet known. ONJ typically develops
after invasive dental procedures such as tooth extractions in a
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small percent of patients with bone metastatic diseases receiv-
ing intravenous antiresorptive therapy [8]. These patients fre-
quently have a history of steroid treatment and multiple che-
motherapies. ONJ also occurs in patients taking oral
antiresorptives for the management of osteoporosis; however,
the incidence in this population is very low [9]. In the majority
of patients taking oral antiresorptives, mucosal healing of
tooth extraction sockets is uneventful even though osteoclastic
bone resorption is hindered [10]. This may imply that osteo-
clast suppression alone is not sufficient to induce ONJ. In-
deed, studies which investigated the effect of bisphosphonates
on long bone fracture healing generally show increased callus
formation, delayed callus remodeling, with no negative over-
all clinical impact on healing [11–13].
Parathyroid hormone (PTH) administered intermittently
stimulates bone turnover and increases bone mass [14].
Teriparatide (rhPTH 1–34) is approved for the treatment of
osteoporosis owing to its bone anabolic action [15].
Teriparatide has been reported to be associated with resolution
of ONJ in several case reports [16] and shown to promote
osseous healing in conjunction with oral surgery in humans
[17]. Considering that N-BPs suppress, while PTH stimulates
bone turnover, the resolution of ONJ and promotion of osse-
ous healing by PTH therapy may be attributed to osteoclast
activity.
Considering the number of patients taking bisphosphonates
who may require a tooth extraction, a better understanding of
the actions of bisphosphonates and PTH on extraction socket
healing would lead to improved patient care. The goals of the
present study were; (1) to determine the effect of the combi-
nation therapy of bisphosphonate and steroid prior to bone
injuries on osseous healing, (2) to compare healing between
tooth extraction sockets and tibial bony defects in
bisphosphonate/steroid-treated rats, and (3) to investigate the
effects of PTH therapy on early wound healing in
bisphosphonate/steroid-affected bones. To achieve the study
goals, ovariectomized-rats were treated with N-BP (ALN) and
steroid (dexamethasone (DEX)), after which, bone injuries
were created in the jaw and tibia. Early osseous wound healing
with and without daily PTH was assessed using micro-
computed tomography (microCT) and histology and results
compared.
Material and methods
Animals and in vivo injections
The experimental protocol was approved by the University
Committee on Use and Care of Animals. Female Sprague
Dawley rats (9 weeks, n =28) were maintained at 22 °C in
12-h light/12-h dark cycles and allowed free access to water
and standard rodent diet. All rats underwent bilateral
ovariectomy (OVX) at 10 weeks of age to induce estrogen-
deficient bone loss experimentally. A bisphosphonate (ALN)
and DEX were subcutaneously administered to induce necrot-
ic lesions in tooth extraction wounds [18, 19]. The ALN
(Sigma-Aldrich, St. Louis, MO) treatment was initiated at
the time of OVX. ALN was administered (0.8 mg/kg), twice
a week for 12 weeks to half of the rats as well as daily DEX
treatment (Tocris, Ellisville, MO) at 1 mg/kg for the last
2 weeks. The other half of rats received vehicle (saline) as
control. The subcutaneous DEX and ALN dosages were cal-
culated based on the body surface area normalization method
[20] and correspond to the human systemic DEX dose (10 mg/
day) and approximately 20 % of the human oral ALN dose
(70 mg/week). At the end of the ALN and DEX (or vehicle)
administration, maxillary right second molars (M2) were ex-
tracted and osseous defects created in the tibia and jaw. Post
tooth extractions, half of ALN/DEX-treated rats and VC-rats
further received daily PTH injections (Bachem, Torrance, CA)
at 80 μg/kg for 2 weeks and the other half daily saline
injections. Hence, a total of four groups (n =7/group) was
established (A/D-VC, A/D-PTH, VC-VC, and VC-PTH;
Fig. 1a). All rats were euthanized 2 weeks post-extractions
of tooth.
Tibial bone defects and tooth extractions
The osseous defects were created in the tibia and jaw
(Fig. 1b, c) under ketamine/xylazine general anesthesia. An
∼10-mm incision was made below the knee joint. The perios-
teum was reflected to expose the bone surface distal to the
proximal metaphysis. A hole (1mm in diameter) was drilled at
4.5 mm distal to the growth plate using a round bur
<2,000 rpm under copious irrigation. Primary closures were
achieved using surgical staples. Next, the maxillary right
second molar was extracted using dental instruments. The
extraction sites were left as open wounds as clinically per-
formed in human tooth extractions.
Microcomputed tomography
At killing, the maxillae and tibiae were dissected, fixed in
10 % formalin, and analyzed using microCT (μCT-100;
Scanco Medical AG, Bruttisellen, Switzerland) to assess bone
parameters in extraction sockets and tibial defects as well as in
intact bone. The maxillae and tibiae were scanned at 10-μm
voxel resolution with an energy level of 70 kV. The extraction
sockets were segmented by the semi-manual contouringmeth-
od [21]. The tibial defects were scanned from 3.7 to 5.9 mm
distal to the growth plate (Fig. 1b). To establish baseline bone
responses to the treatment, the metaphyseal bone of the prox-
imal tibiae from 1.2 to 3.5 mm distal to the growth plate and
the interradicular bone between the mesial and distal roots of
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the maxillary first molars (Fig. 1c) were assessed as well [22].
Data were analyzed using the built-in Scanco software.
Histomorphometry
The maxillae and tibiae were demineralized in 10 % ethylene-
diaminetetraacetic acid at 4 °C, paraffin embedded, and sec-
tioned at 5 μm. Hematoxylin and eosin, tartrate resistant acid
phosphatase, and Masson’s trichrome staining was performed
following standard protocols and/or manufacturer’s instructions
(386A, HT15, Sigma-Aldrich, St. Louis, MO) [23]. Blood
vessels in the extraction wounds were immunohistochemically
stained. Briefly, sections were deparaffinized, nonspecific pro-
tein blocked, and incubated overnight with a rabbit von
Willebrand factor (vWF) antibody (ab6999, Abcam, Cam-
bridge,MA). Goat anti-rabbit IgG (AP307,Millipore) was used
as a secondary antibody and proteins developed with 3,3-di-
aminobenzidine (Vector Laboratories, Burlingame, CA). Sec-
tions were counterstained with hematoxylin. Terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining was performed to assess apoptotic cells in
the tibial defects (FragEL™ DNA Fragmentation Detection
Kit, EMD Chemicals, Gibbstown, NJ). Empty osteocyte lacu-
nae were quantified within 100 μm depth of bone surface.
Necrotic bone area, defined as the portion of bone with greater
than or equal to 10 adjacent empty osteocyte lacunae, was
measured [24]. Polymorphonuclear cell (PMN) infiltration
was assessed by quantifying inflammatory cell numbers in soft
tissue within 100 μm of the bone surface (area of interest
(AOI), 0.1×2.5 mm). Collagen deposition and vWF+ blood
vessels were assessed in the soft tissue next to the bone surface
(AOI, 0.4×2.5 mm). All histomorphometric analyses
were performed using Image-Pro (Media Cyberrnetics,
Bethesda, MD).
Statistics
Statistical analysis was conducted with SYSTAT 12 (Systat
Software, Chicago, IL) and InStat (GraphPad Software, San
Diego, CA). Analysis of variance was performed for multiple
groups with a Tukey’s post hoc test. For comparisons within
the group, paired t test was conducted. The PTH effect on the
mucosal wound closure was assessed using Fisher’s exact test.
An α-level of 0.05 was used for statistical significance. Re-
sults are presented as mean±SEM unless specified.
Results
PTH actions in intact tibiae were greatest in rats treated
with ALN/DEX
Bone volume and bone mineral density (BMD) in the intact
tibial metaphysis were significantly higher in the ALN/DEX
treatment groups vs. vehicle control (Fig. 2a–f). PTH follow-
ing ALN/DEX showed a non-significant trend toward higher
bone volume and BMD versus ALN/DEX-VC. PTH had little
bone anabolic effect in the group without the ALN/DEX
treatment. However, trabecular thickness was significantly
higher in the VC-PTH vs. control (Fig. 2d). Interestingly, the
bone anabolic effect of PTHwas more pronounced after ALN/
DEX than after VC treatment in the intact tibial metaphysis
(Fig. 2g).
PTH actions in wounded tibiae were blunted in rats treated
with ALN/DEX
In the tibial wounds, bone fill and BMD were significantly
higher in the ALN/DEX treatment groups vs. vehicle control
(Fig. 3a–f). PTH significantly enhanced bone fill, trabecular
















Fig. 1 Experimental schedule. a Rats (n =14) received ALN for
12 weeks and dexamethasone for 2 weeks before tooth extraction and
osseous defect surgeries. Another14 rats received vehicle control (saline).
Immediately after the surgeries, half of rats in each group received daily
PTH administration (80 μg/kg) for 2 weeks and the remaining half
vehicle control. b MicroCT scanning was performed in the proximal
tibiae between 1.2 and 3.5 mm from the growth plate to determine the
treatment effect on undisturbed trabecular bone. Scanning between 3.7
and 5.9 mm away from the growth plate was used to asses osseous
healing (arrowhead). c ThemicroCTscanning sites in the maxillae: tooth
extraction wounds (arrow) and the interradicular bone (arrowhead) of
the neighboring tooth. d A schematic drawing of a tooth extraction
socket. Tissue area (TA) was defined as the area of an extraction socket
and surrounding bone
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thickness, and BMD regardless of the presence or absence of
the ALN/DEX treatment. The PTH effect observed in wound-
ed controls was very different from that observed in the intact
tibiae (Figs. 3b vs. 2b). The bone anabolic effect of PTH was
significantly more robust after the VC than after ALN/DEX
treatment (Fig. 3g), suggesting that the ALN/DEX treatment
had a restrictive impact on the PTH anabolic effect in the tibial
osseous wounds.
PTH promoted osteocyte and bone marrow cell survival
in tibial wounds
Healing of the tibial wounds was further assessed in histologic
sections. Tissue area (TA) was defined as the area surrounded
by the cortical bone (Fig. 4a). Bone fill (bone area (BA)/TA)
was significantly higher in the ALN/DEX treatment groups
versus vehicle control (Fig. 4b). Significantly higher bone fill
was noted in the PTH-treated groups irrespective of the pres-
ence or absence of the ALN/DEX treatment. These results
were consistent with those of the microCT assessment
(Fig. 3b). Periosteal callus formation was observed in the
ALN/DEX-PTH group but statistical significance was not
reached (Fig. 4c). The ALN/DEX treatment significantly re-
duced osteoclast surface compared with control with a sub-
stantial reduction by PTH following ALN/DEX (Fig. 4d).
Osteoblast surface was not affected by the ALN/DEX treat-
ment but PTH resulted in significantly higher osteoblast sur-















































































































aFig. 2 Treatment effect on
undisturbed bone. a
Representative longitudinal and
cross-sectional images of the
undisturbed tibiae. The ALN/
DEX treatment resulted in
significantly higher bone mass
(b), trabecular numbers (c), BMD
(f), and lower trabecular
separation (e) compared with the
VC treatment groups. PTH for
2 weeks significantly increased
trabecular thickness regardless of
the treatment (d). A
nonsignificant increase by PTH
was noted in bone mass (b) and
BMD (f) in the ALN/DEX
treatment group. When the bone
mass increase by PTH was
compared between the ALN/
DEX and VC treatment groups, a
significantly greater increase was
noted in the ALN/DEX treatment
group (g). *p<0.05; **p<0.01;
***p <0.001 versus control
(VC-VC)
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empty osteocyte lacunae and necrotic bone were significantly
lower in PTH-treated groups regardless of the presence or
absence of the ALN/DEX treatment (Fig. 4f, g), suggesting
that PTH promoted osteocyte survival. Apoptotic bone mar-
row cells in the defects were visualized with TUNEL staining
and histomorphometrically assessed. PTH significantly re-
duced numbers of TUNEL-positive apoptotic bone marrow
cells compared with control irrespective of the presence or
absence of the ALN/DEX treatment (Fig. 4h).
PTH promoted tooth extraction wound healing
after ALN/DEX treatment
Next, treatment effects were assessed in the jaw. In the
interradicular bone near the tooth extraction site (Fig. 1c),
the ALN/DEX treatment resulted in significantly higher bone
volume and BMD than control (Fig. 5a). The average bone
anabolic effect of PTHwas significantly higher in the VC than
ALN/DEX treatment group. In the tooth extraction sockets,
bone fill and BMDwere significantly higher in the ALN/DEX
treatment groups than controls (Fig. 5b). PTH significantly
enhanced bone fill and BMD regardless of the presence or
absence of the ALN/DEX treatment. However, the average
PTH bone anabolic effect was significantly less in the ALN/
DEX vs. VC treatment group, again indicating that the ALN/
DEX treatment suppressed bone anabolism by PTH in the
tooth extraction wounds.
PTH rescued ALN/DEX-associated deterred tooth extraction
wound healing
Tooth ex t r ac t ion wound hea l ing was asses sed
histomorphometrically. Representative photomicrographs of
the trichrome-stained sections of the tooth extraction wounds
at 2 weeks post-extractions are shown in Fig. 6a. Open
wounds with exposed bone were noted in six rats in the
ALN/DEX-VC group and 1 rat in the ALN/DEX-PTH group.
In vehicle control (VC-VC), three rats showed open wounds,
while no open wound was noted in the VC-PTH group. PTH
administration after tooth extractions promoted healing re-
gardless of the presence or absence of the ALN/DEX treat-
ment with significant improvement after the ALN/DEX treat-
ment. TAwas defined as the portion of the maxilla surround-
ing the roots of M2 (Fig. 1d) and bone area (BA/TA) was
assessed. The histomorphometric assessment revealed signif-
icantly higher bone area in the ALN/DEX-VC, ALN/DEX-
PTH and VC-PTH groups vs. control (Fig. 6b), which was




















































































































Fig. 3 Treatment effect on the
tibial defects. a Representative
cross-sectional images of the
tibial defects. Regardless of
treatment, significantly higher
bone mass (b), trabecular
numbers (c), BMD (f), and lower
trabecular separation (e) were
noted in the treatment groups vs.
control. PTH significantly
increased trabecular thickness in
the ALN/DEX and VC treatment
groups but the ALN/DEX
treatment alone had no effect on
trabecular thickness (d).
Although PTH further increased
bone mass (b) and BMD (f) after
the ALN/DEX treatment, an
average bone mass increase by
PTH was significantly less after
ALN/DEX compared with VC
(g). ***p <0.001 versus control
(VC-VC); †††p <0.001 versus the
ALN/DEX-VC group
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DEX treatment significantly suppressed osteoclast surface
compared with control (Fig. 6c). PTH resulted in significantly
higher osteoclast surface after the VC treatment but not after
the ALN/DEX treatment. Likewise, significantly higher oste-
oblast surface by PTH was noted after the VC treatment but
not after the ALN/DEX treatment (Fig. 6d). The ALN/DEX
treatment had no apparent effect on osteoblast surface. The
numbers of empty osteocyte lacunae and necrotic bone were
significantly higher in the ALN/DEX-VC group versus con-
trol (Fig. 6e, f). PTH significantly reduced the numbers of
empty osteocyte lacunae and presence of necrotic bone. Sim-
ilarly, PTH significantly reduced the numbers of empty lacu-
nae and necrotic bone when the VC-VC and VC-PTH groups
were compared, suggesting that PTH promoted osteocyte
survival. PMN infiltration was also significantly higher in
the ALN/DEX-VC group and PTH significantly reduced
PMNs in the ALN/DEX-PTH group (Fig. 6g). Connective
tissue maturation as measured by collagen apposition was
lower in the ALN/DEX-VC group vs. control (Fig. 6h); how-
ever, PTH significantly enhanced the collagen apposition
regardless of presence or absence of the ALN/DEX treatment.
There were no differences noted in the numbers of blood
vessels between groups (Fig. 6i).
Discussion
The ALN/DEX treatment resulted in high bone mass in both
the tibia and jaw as anticipated [26]. However, its effect on
osseous wound healing was distinct; the ALN/DEX treatment
enhanced early osseous healing in the tibial wounds by in-
creasing bone fill, while it impaired tooth extraction wound
healing with exposed bone. The effect of bisphosphonate
therapy on osseous healing in rat long bones has previously
been reported in the literature [26, 27]. Those reports agree
that bisphosphonate therapy promotes osseous repair by en-
hancing formation, mineralization, and mechanical strength of
callus, but also slows callus remodeling. Hence, our result of
high bone fill by ALN/DEX is consistent with the literature.
Despite the positive impact on tibial wound healing, in con-
trast, ALN/DEX impaired tooth extraction wound healing in

















































































































































assessments of tibial wound
healing. a A diagram of the cross-
sectional view of a tibial defect
indicating the tissue area (TA).
Both the ALN/DEX and PTH
treatment resulted in significantly
higher bone area vs. control (b).
PTH after the ALN/DEX
treatment significantly increased
bone area. No differences were
noted in periosteal callus
formation between groups, but a
trend of more periosteal callus in
the ALN/DEX-PTH group vs.
control was observed (c). The
ALN/DEX treatment
significantly suppressed
osteoclast surface vs. control with
further significant reduction in the
ALN/DEX-PTH group (d). The
ALN/DEX treatment had no
effect on osteoblast surface vs.
control. PTH significantly
increased osteoblast surface after
ALN/DEX (e). PTH therapy
significantly suppressed the
numbers of empty osteocyte
lacunae and necrotic bone area
regardless of other treatment (f ,
g). TUNEL+ cells in the bone
marrow were significantly
reduced by PTH compared with
control (h). *p<0.05; **p <0.01;
***p <0.001 versus control (VC-
VC); †p <0.05; ††p <0.01 versus
the ALN/DEX-VC group
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The combined use of bisphosphonates and steroid has been
demonstrated to be associated with the development of ne-
crotic lesions in rats [18, 19]. The impaired extraction wound
healing by ALN/DEX observed in our study is consistent with
these reports. It should be mentioned that although the
bisphosphonate/steroid treatment impaired tooth extraction
wound healing in rats, such a drug combination does not
always hinder wound healing in other animals [28].
The difference in osseous healing between the tibia and jaw
may be similar to what is seen in patients on antiresorptive
therapy. ONJ uniquely occurs in the jaw but not in long bones
[29]. Tooth extractionwounds are different from tibial osseous
wounds in that (1) they are open wounds exposed to the oral
cavity where numerous oral pathogens inhabit and dense
bacterial colonization occurs [30], (2) the extraction wounds
are subjected to repeated mechanical trauma from chewing,
(3) the extraction sockets are surrounded by dense bundle
bone while the tibial wounds are exposed to the abundance
of the bone marrow milieu, (4) the embryologic origin of the
maxillae and mandibles (pharyngeal arch 1) is distinct from
long bones [31], and (5) the bone formation pattern of the
alveolar bone is different from that of long bones
(intramembranous vs. endochondral bone formation) [32].
Considering these differences, tooth extraction wound healing
appears to be distinct from long bone wound healing. How-
ever, the exact mechanism of the different healing responses
between the tibia and jaw is unclear. The etiopathological role
of oral bacteria in ONJ has been proposed; when bacterial
infection, such as periodontitis, was experimentally induced in
rats receiving bisphosphonates, necrotic lesions developed,
however, no such lesions occurred in rats without bisphos-
phonate therapy [33, 34]. In support of this hypothesis, Lopez-
Jornet et al. reported that antibiotic administration prior to
tooth extract ions in rats on the combination of
bisphosphonates and DEX significantly reduced the incidence
of necrotic lesions [35]. Whether bisphosphonate treatment
exacerbates bacterial infection or not was studied using a rat
model of infectious osteomyelitis [36]. In this study
gentamycin-sensitive Staphylococcus aureus -treated implants
were placed in rat tibiae with or without ALN treatment. High-
grade infection and necrotic bone formation were found with
ALN treatment, while neither infection nor necrotic bone was
noted with placebo. Gentamycin therapy ameliorated the in-
fection and resulted in no necrotic bone formation. Although
the study was osteomyelitis focused, the findings support the
etiopathological role of bacteria in ONJ.
In the current study, intermittent PTH administration for
2 weeks after VC treatment resulted in significantly higher
bonemass in intact maxillae but not in intact tibiae. The difference
in bone responses to PTH is likely due to the presence or absence
of trabecular bone. In this study, the metaphyseal trabecular bone
area between 1.2 and 3.5 mm distal to the growth plate was
assessed to establish baseline bone responses to PTH. As the
assessed bone site corresponds to the distal end of themetaphyseal
trabecular bone in the proximal tibiae, the trabecular bone at this
site would be resorbed because of OVX in the VC-treated rats.
Accordingly, the trabeculation was scarce when PTH therapy was
initiated. The relatively high BMD values of the maxillae in the
VC-VC group suggests the trabecular structure was maintained





















































































































































































































Fig. 5 Treatment effect on the maxillae. a The result of microCT
assessment of undisturbed maxillae. Regardless of treatment, significant-
ly higher bone mass and BMD were found in the treatment groups vs.
control. The ALN/DEX treatment significantly increased trabecular
thickness and decreased trabecular separation compared with control.
No PTH anabolic effect was observed after the ALN/DEX treatment,
while PTH increased bone mass significantly after VC. b The result of
microCTassessment of tooth extraction wounds. Both the ALN/DEX and
PTH treatments resulted in significantly higher bone mass, trabecular
thickness, and BMD than control. Although PTH significantly increased
bone mass and BMD after ALN/DEX, an average increase in bone mass
by PTH was significantly smaller after ALN/DEX than VC. *p<0.05;
**p <0.01; ***p <0.001 versus control (VC-VC); †p <0.05 versus the
ALN/DEX-VC group
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group points to significant trabecular bone loss. Therefore, in the
intact tibiae that the PTH anabolic effect was not observed was
likely due to a trabeculation deficit. Rats in which ALN/DEX
treatment was initiated immediately after OVX had greater trabec-
ular bone as evidenced by the highBV/TVandBMDvalues in the
ALN/DEX-VCgroup. In theALN/DEX-treated rats, PTH therapy
augmented BV/TV and BMD. In fact, when the PTH anabolic
effect was compared between ALN/DEX and VC treatment,
significantly higher bone volume was found in the ALN/DEX-
treated rats. These findingsmay suggest that the amount of existing
trabecular bone is a determinant of the degree of PTH anabolic
effect in the metaphysis. It is also possible that the short duration
(2 weeks) of PTH treatment was not long enough to support
significant anabolism at this site. The tibial bone defects were
made at the edge of the diaphysis where little trabecular bone, if
any, existed. Even the defects were created in such a sparse
trabecular bone area in the VC-treated rats, PTH significantly
promoted bone fill. PTH also enhanced bone fill in the defects
significantly after the ALN/DEX treatment. When the PTH ana-
bolic effect was compared between the osseous defects and undis-
turbed bone, more powerful PTH anabolic effect was noted in the
osseous defect than in undisturbed bone in this study (approxi-
mately 47 vs. 6 %). PTH has been shown to promote osseous
healing in osteoporotic women [37]. The PTH anabolic effect has
also been shown to be pronounced in rapidly growing animals
[38]. Nakajima et al. reported that low doses of PTH, which did
not increase systemic bone mass, was sufficient to promote osse-






























































































































































































Fig. 6 Histomorphometric assessments of extraction wound healing. (a)
Representative images of frontal-sections of the extraction wounds. Six
rats developed necrotic lesions in the ALN/DEX-VC group and only one
in the ALN/DEX-PTH group. Both the ALN/DEX and PTH treatments
resulted in significantly higher bone area vs. control (b). The ALN/DEX
treatment significantly suppressed, and PTH after VC, significantly in-
creased osteoclast surface (c). PTH significantly increased osteoblast
surface after VC but not after ALN/DEX (d). Significantly higher num-
bers of empty osteocyte lacunae and necrotic bone area were noted in the
ALN/DEX-VC group vs. control. PTH suppressed the numbers of empty
lacunae and necrotic bone area significantly after ALN/DEX and after VC
(e , f). PMN infiltration was significantly higher in the ALN/DEX-VC
group versus control. PTH dramatically suppressed PMN infiltration
when given after ALN/DEX (g). Significantly lower collagen apposition
was noted in the ALN/DEX-VC group vs. control. PTH increased colla-
gen apposition significantly after ALN/DEX and after VC (h ). No
treatment regimen altered blood vessel numbers (i). *p < 0.05; **p <
0.01; ***p < 0.001 versus control (VC-VC); †p < 0.05; ††p < 0.01 versus
the ALN/DEX-VC group
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suggest that PTH’s anabolic actions are greatly enhanced in bone
with a high metabolic state. It should be mentioned that although
PTH significantly augmented bone fill in the defects after ALN/
DEX, this increase was smaller than that after VC treatment,
suggesting a possible blunting effect of ALN/DEX treatment on
the PTH anabolic effect [40].
In extraction wounds, PTH rescued ALN/DEX-induced
impaired healing evidenced by high bone fill and promotion
of soft tissue coverage. PTH’s ability to promote healing of
ONJ in osteoporotic patients has been reported in case studies
[16], however, its mechanisms are unknown. Our study may
provide a biological explanation. In the current study, the
ALN/DEX treatment significantly suppressed osteoclasts in
the extraction wounds. Osteoclast recovery, however, ap-
peared to not be critical for healing since osteoclast surface
was significantly suppressed in the healed wounds of the
ALN/DEX-PTH group. Rather, the reduction of empty oste-
ocyte lacunae appeared to be associated with healing. PTH
significantly reduced the empty lacunae in both the ALN/
DEX- and VC-treated rats, suggesting that PTH may promote
osteocyte survival in extraction wounds. The significant re-
duction in empty osteocyte lacunae was observed not only in
the extraction wounds but also in the tibial defects. In the tibial
defects, it is likely that the surgical drill created damage in the
bone and induced osteocyte death. PTH significantly promot-
ed osteocyte survival in both the ALN/DEX and VC-treated
groups. Furthermore, PTH appeared to promote the survival
of bone marrow cells as suggested by the numbers of
TUNEL+ bone marrow cells that were significantly sup-
pressed by PTH in the tibial defects. Intermittent PTH is
known to have antiapoptotic effects in mature osteo-
blasts [41], but our findings suggest that PTH might
have antiapoptotic effects on other cell types including
osteocytes in osseous wounds. In this study, PTH sup-
pressed PMN infiltration and promoted collagen apposi-
tion significantly in the extraction wounds. Although
unclear, we speculate that the suppression of osteocyte
death by PTH reduced inflammatory responses and
therefore suppressed PMN infiltration, and such a dim-
inution in inflammatory responses promoted soft tissue
healing by increasing collagen apposition.
Abtahi et al. compared the incidence of necrotic lesions with
and without wound coverage post-extractions in rats on ALN/
DEX and found that all extraction wounds developed necrotic
lesions when the wounds were left open, but with the wound
coverage, no necrotic lesions occurred [42]. In the present study,
the tooth extraction wounds were left open, while the tibial
defects were closed. Extraction wounds are typically left open
in humans, so it is possible that if the oral wounds were closed in
this study, they could have healed in a similarmanner to the tibial
wounds. The observed differences in this study could be, there-
fore, to a small extent attributed to the presence or absence of
wound closure. Rats heal rapidly after tooth extraction; epithelial
coverage occurs in approximately 8 days and bone fill happens
in approximately 3 weeks [5]. Assessment of healing at 2 weeks
was chosen since a primary goal for this study was to evaluate
short-term actions of PTH during the course of wound healing.
However, this time period could fall short and the outcome of
this study may be different if PTH therapy had been extended.
This study shows that ALN and DEX treatment restricted
tooth extraction wound healing in the jaw. Intermittent PTH
rescued bisphosphonate/dexamethasone-induced necrotic le-
sions by promoting soft tissue healing. The findings of this
study suggest that intermittent PTH therapy could be consid-
ered to prevent ONJ in osteoporosis patients receiving ALN
and steroid therapies.
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